How to Get Cagrilintide in the US

Most “how to get [peptide]” guides work because there are real routes to compare. For BPC-157 or TB-500 you can lay the three legal channels — telehealth, in-person clinic, direct compounding prescription — side by side and weigh them on cost and speed. Cagrilintide breaks that format. Run it through the same table and nearly every cell comes back the same answer: not available. That is not an oversight in this guide; it is the honest 2026 status of the compound, and understanding why each route is closed is more useful than pretending one is open.

This page is the route-comparison companion to our cagrilintide prescription page, which goes deeper on the prescribing mechanics. Here the focus is the practical map: which access paths people try, which actually exist, and what the realistic forward route looks like.

The route comparison, run honestly

When people ask how to get a peptide, they are usually picturing one of four channels. Here is how each one lands for standalone cagrilintide in 2026.

A compounded prescription (the 503A route). This is how some non-approved peptides are legally obtained: a licensed prescriber writes a script, and a 503A compounding pharmacy prepares it from a permitted bulk substance. It does not work for cagrilintide. Compounding pharmacies can only build from FDA-approved drugs or from substances on the agency’s permitted bulk lists, and cagrilintide is neither. It is a proprietary, patent-protected molecule still in clinical development, which puts it outside the compounding system entirely. The contrast with a peptide like BPC-157 — which has a genuine compounding conversation around it — is the whole point: the door that is ajar for some compounds is bolted shut for this one.

Telehealth. Telehealth platforms feel like a catch-all route because they prescribe so many weight-management medications now. But a telehealth visit cannot conjure a supply chain that does not exist. A prescriber can only issue a prescription that a licensed pharmacy can lawfully fill, and no US pharmacy can lawfully dispense or compound standalone cagrilintide. A reputable telehealth service will tell you this and pivot you toward an approved option; a service that claims to “get you on cagrilintide” is either confusing it with an approved GLP-1 or steering you toward a gray-market vial dressed up as a clinical program.

An in-person clinic. The same constraint applies in a physical clinic as on a screen. A clinician in a wellness or weight-loss clinic is still bound by what a pharmacy can lawfully supply. An in-person visit adds nothing that unlocks cagrilintide specifically; it simply moves the same dead end into an exam room. Where in-person clinics add real value is for approved medications and for the medical evaluation behind them — not for accessing an investigational molecule.

A registered clinical trial. This is the one genuinely legitimate route to cagrilintide exposure in 2026, and it is a real one. Cagrilintide has been studied extensively, including as a standalone arm in large phase 3 trials. Participating in an active, IND-governed study is lawful, supervised, and free of the supply-chain problem — because the trial sponsor provides the investigational product under FDA oversight. It is not a route to “getting” the drug for personal ongoing use, but it is the only setting where a person legally receives cagrilintide today.

Note: If a website, clinic, or “telehealth” service offers to sell or prescribe standalone cagrilintide outside a registered trial, that is a signal to walk away, not a workaround. The legitimate-route table really does come up nearly empty — anything filling it is operating outside the rules.

Why “investigational” is the word that decides everything

The reason every retail route fails traces back to a single legal status: cagrilintide is investigational. It has not received FDA approval, which means there is no labeled, manufactured product a pharmacy can stock and dispense. And because it is a patented molecule still owned and developed by its sponsor, it is not on the compounding bulk lists either. A lawful prescription needs two legs — a legal prescriber and a legal pharmacy that can fill it — and for standalone cagrilintide the second leg simply does not exist. Our prescription page walks through that mechanics in detail.

This is a different situation from the broader 2026 peptide picture. Some peptides saw movement in their FDA standing this year, and there is an active compounding pathway for a handful of them. Cagrilintide is not part of that story. It is not waiting on a compounding decision; it is a commercial pharmaceutical candidate moving through the standard new-drug approval process, where the only finish line that opens access is full FDA approval of a finished product.

It is also worth being precise about what cagrilintide is not: it is not a controlled substance and carries no DEA schedule. People sometimes assume “you can’t get it” means “it’s a scheduled drug.” That is not the case. The barrier is not criminal scheduling — it is the absence of any approved or compoundable product to lawfully supply.

The realistic forward path: CagriSema, not standalone cagrilintide

For most people asking how to get cagrilintide, the underlying goal is weight management, and the real news is about the combination. CagriSema pairs cagrilintide 2.4 mg with semaglutide 2.4 mg in a single once-weekly injection. Novo Nordisk submitted a New Drug Application to the FDA on December 18, 2025, with a review expected during 2026. The submission rested on the REDEFINE phase 3 program, where the combination produced roughly 20%+ average weight loss over 68 weeks in trial participants.

Two cautions matter here. First, submitted is not approved: as of mid-2026 CagriSema remains investigational and is not available by prescription anywhere in the US. Second, the product moving toward approval is the combination, not standalone cagrilintide. If CagriSema is approved, it will be a fixed-dose semaglutide-plus-cagrilintide medication — which still does not create a route to cagrilintide on its own. So the honest forward map is: watch the CagriSema decision, and understand that even a “yes” delivers a combination drug, not the standalone compound.

What actually works for you right now

If your interest in cagrilintide is curiosity about the science, our what-is-cagrilintide explainer and the benefits and weight-loss context cover the evidence without any pretense of an access route.

If your interest is genuinely weight loss and you want something available today, the productive move is to step over to the approved options. Semaglutide and tirzepatide are FDA-approved, have real prescribing pathways, and are reachable through legitimate telehealth and in-person care. Our guide to how to get semaglutide walks through those routes the way this page would if cagrilintide actually had any. A telehealth or clinic evaluation that ends in an approved medication is the closest thing to a working “route” in this space — it is just a route to a different, approved drug.

And if your interest is participating in research, clinical-trial registries list active cagrilintide and CagriSema studies; eligibility is specific and screening is involved, but it is the one lawful way to receive the compound under supervision.

The bottom line

There is no legal way to buy or be prescribed standalone cagrilintide in the US in 2026. It is investigational, it is not compoundable, and the telehealth and clinic channels that work for other compounds cannot manufacture access that the supply chain does not provide. The only lawful exposure is a registered clinical trial, and the realistic forward path for weight management is CagriSema — the combination product — if and when the FDA approves it. Until then, any vendor or service promising standalone cagrilintide is gray-market, not a route. For people whose goal is weight loss today, an approved GLP-1 medication through a legitimate provider is the genuine option, and it is the one this site will help you understand. Status here is current as of June 2026 and can change as the CagriSema review proceeds.